Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.

Drug-resistant tuberculosis poses a significant problem for treatment. The mechanisms of resistance to the front-line drug isoniazid (INH) are complex and can be mediated by katG, inhA and other unknown genes. To identify the percentage of INH-resistant strains with no katG or inhA mutation, this study characterized a panel of 28 clinical isolates of Mycobacterium tuberculosis and five mutants derived from H37Rv resistant to INH. Seventeen of 33 resistant strains (51 %) had katG mutations with 12 of the 17 strains having the most common KatG Ser315Thr mutation. Three of the 17 strains with the KatG 315 mutation had an additional mutation in the inhA promoter and were resistant to a high level of INH. Seventeen of the 33 INH-resistant strains (51 %) had inhA mutations. The most common inhA promoter mutation was -15C-->T and was present in 13 of the 17 inhA mutations. This promoter mutation occurred alone without katG mutations and was associated with a low level of INH and ethionamide resistance. However, other inhA mutations were associated with katG mutations. No mutations were found in the ndh gene. Three of 33 strains (9 %) had no mutations in katG, inhA or ndh, indicating that their resistance was due to a new mechanism of resistance. Detection of the KatG Ser315Thr mutation and the -15C-->T inhA mutation accounted for 76 % (25/33) of the INH-resistant strains and should be useful for rapid detection of INH-resistant strains by molecular tests.

[1]  S. Niemann,et al.  Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. , 2012, Journal of clinical microbiology.

[2]  F. Drobniewski,et al.  Molecular Analysis of Isoniazid-Resistant Mycobacterium tuberculosis Isolates from England and Wales Reveals the Phylogenetic Significance of the ahpC −46A Polymorphism , 2005, Antimicrobial Agents and Chemotherapy.

[3]  C. Vilchèze,et al.  Altered NADH/NAD+ Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria , 2005, Antimicrobial Agents and Chemotherapy.

[4]  S. Siddiqi,et al.  Identification of a Mycobacterium tuberculosis Strain with Stable, Low-Level Resistance to Isoniazid , 2004, Journal of Clinical Microbiology.

[5]  J. T. Crawford,et al.  ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[6]  D. Bakonyte,et al.  Molecular Characterization of Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates in Lithuania , 2003, Antimicrobial Agents and Chemotherapy.

[7]  M. Nguyen,et al.  1H and 13C NMR characterization of hemiamidal isoniazid-NAD(H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. , 2003, Chemistry.

[8]  Stefania Girotto,et al.  Reduced Affinity for Isoniazid in the S315T Mutant ofMycobacterium tuberculosis KatG Is a Key Factor in Antibiotic Resistance* , 2003, The Journal of Biological Chemistry.

[9]  Teresa Quitugua,et al.  Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[10]  M. Raviglione.  The TB epidemic from 1992 to 2002. , 2003, Tuberculosis.

[11]  Audrey S. M. Teo,et al.  Novel Mutations in ndh in Isoniazid-Resistant Mycobacterium tuberculosisIsolates , 2001, Antimicrobial Agents and Chemotherapy.

[12]  C. Locht,et al.  Activation of the pro-drug ethionamide is regulated in mycobacteria. , 2000, The Journal of biological chemistry.

[13]  L. Bekker,et al.  Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  I. H. Lim,et al.  Contribution of kasA Analysis to Detection of Isoniazid-Resistant Mycobacterium tuberculosisin Singapore , 1999, Antimicrobial Agents and Chemotherapy.

[15]  N. Wengenack,et al.  Evidence for differential binding of isoniazid by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T). , 1998, Biochemistry.

[16]  David A. Mead,et al.  Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP synthase by isoniazid , 1998 .

[17]  T. Weisbrod,et al.  NADH Dehydrogenase Defects Confer Isoniazid Resistance and Conditional Lethality in Mycobacterium smegmatis , 1998, Journal of bacteriology.

[18]  J. Sacchettini,et al.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.

[19]  A. Telenti,et al.  Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level , 1997, Journal of clinical microbiology.

[20]  Clifton E. Barry,et al.  Compensatory ahpC Gene Expression in Isoniazid-Resistant Mycobacterium tuberculosis , 1996, Science.

[21]  T. Wilson,et al.  ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex , 1996, Molecular microbiology.

[22]  S. Cole,et al.  Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.

[23]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[24]  D. Young,et al.  Transformation with katG restores isoniazid‐sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations , 1993, Molecular microbiology.

[25]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[26]  B. U. Bowman,et al.  Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra , 1985, Antimicrobial Agents and Chemotherapy.

[27]  G. Middlebrook.  Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. , 1954, American review of tuberculosis.

[28]  T. Feltwell,et al.  Erratum: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[29]  S T Cole,et al.  Mechanisms of drug resistance in Mycobacterium tuberculosis. , 1996, Current topics in microbiology and immunology.

[30]  D van Soolingen,et al.  Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. , 1996, The Journal of infectious diseases.